

Research article

Open Access

Biochemical and structural characterization of alanine racemase from *Bacillus anthracis* (Ames)

Rafael M Couñago¹, Milya Davlieva², Ulrich Strych³, Ryan E Hill¹ and Kurt L Krause*¹

Address: ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Biochemistry Rice University, Houston, TX, USA and ³Department of Biology and Biochemistry, University of Houston, Houston, TX, USA

Email: Rafael M Couñago - rafael.counago@otago.ac.nz; Milya Davlieva - milyadav@hotmail.com; Ulrich Strych - strych@UH.EDU; Ryan E Hill - ryane.hill@gmail.com; Kurt L Krause* - kurt.krause@otago.ac.nz

* Corresponding author

Published: 20 August 2009

Received: 6 January 2009

BMC Structural Biology 2009, 9:53 doi:10.1186/1472-6807-9-53

Accepted: 20 August 2009

This article is available from: <http://www.biomedcentral.com/1472-6807/9/53>

© 2009 Couñago et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: *Bacillus anthracis* is the causative agent of anthrax and a potential bioterrorism threat. Here we report the biochemical and structural characterization of *B. anthracis* (Ames) alanine racemase (Alr_{Bax}), an essential enzyme in prokaryotes and a target for antimicrobial drug development. We also compare the native Alr_{Bax} structure to a recently reported structure of the same enzyme obtained through reductive lysine methylation.

Results: *B. anthracis* has two open reading frames encoding for putative alanine racemases. We show that only one, *dall*, is able to complement a D-alanine auxotrophic strain of *E. coli*. Purified Dall, which we term Alr_{Bax}, is shown to be a dimer in solution by dynamic light scattering and has a V_{max} for racemization (L- to D-alanine) of 101 U/mg. The crystal structure of unmodified Alr_{Bax} is reported here to 1.95 Å resolution. Despite the overall similarity of the fold to other alanine racemases, Alr_{Bax} makes use of a chloride ion to position key active site residues for catalysis, a feature not yet observed for this enzyme in other species. Crystal contacts are more extensive in the methylated structure compared to the unmethylated structure.

Conclusion: The chloride ion in Alr_{Bax} is functioning effectively as a carbamylated lysine making it an integral and unique part of this structure. Despite differences in space group and crystal form, the two Alr_{Bax} structures are very similar, supporting the case that reductive methylation is a valid rescue strategy for proteins recalcitrant to crystallization, and does not, in this case, result in artifacts in the tertiary structure.

Background

Bacillus anthracis is a soil-dwelling, spore-forming, Gram-positive bacterium that is the causative agent of the zoonotic disease anthrax. Although the disease is most common in wild and domestic mammals, it can also occur in humans when exposed to infected animals or liv-

ing spores [1]. The severity of anthrax in humans depends on the route of infection. Inhalation of *B. anthracis* spores can lead to the most severe form of the disease, historically associated with a case-fatality rate as high as 85% [2,3]. The high mortality rate, the existence of a respiratory route of infection and the great resistance of its spores has

made *B. anthracis* the subject of biological warfare research programs in many countries for over 60 years [4]. The United States Centers for Disease Control and Prevention (CDC) has classified anthrax as a category A bioterrorism agent, posing the greatest possible threat to public health and with the ability to spread across large areas [5]. In 2001, the Ames strain of *B. anthracis* was used in a series of bioterrorist attacks that resulted in five fatalities and cost billions of dollars to the US economy [6,7]. As *B. anthracis* spores are resilient, remaining viable and infective for many years, efforts to decontaminate affected facilities are time-consuming and costly. Therefore, it would be of significant importance to public health and security to develop new strategies aimed at containing *B. anthracis* spores upon their release into the environment.

Alanine racemase (EC 5.1.1.1) is an essential enzyme in prokaryotes. The enzyme utilizes a pyridoxal 5'-phosphate (PLP) cofactor to catalyze the racemization of L-alanine to D-alanine, an essential component of the peptidoglycan layer in bacterial cell walls. The lack of alanine racemase function in eukaryotes has made this enzyme an attractive target for antimicrobial drug development [8,9]. In *B. anthracis*, the gene coding for alanine racemase, *dal1*, is one of only four genes up-regulated during sporulation [10]. The *dal1* gene product (Alr_{Bax}) is found on the spores' outermost layer [10] and addition of alanine racemase inhibitors has been shown to promote germination of *B. anthracis*' spores [11] while endogenous production of D-alanine, mediated by alanine racemase, inhibits germination [12]. Triggering the premature germination of *B. anthracis* spores by spraying alanine racemase inhibitors on affected areas may therefore be a strategy to speed decontamination efforts and reduce the risk of infection in humans. Further, Alr_{Bax} has recently been reported as an immunodominant protein in a proteomic analysis of the *B. anthracis* spore induced immunome [13,14]. Given the importance of three-dimensional information in structure-aided inhibitor design [15-17] and its growing role in vaccine development [18-20], structural studies on Alr_{Bax} are crucial to both of these goals.

The first structural studies of alanine racemases, which were performed on the enzyme isolated from *Geobacillus* (then *Bacillus*) *stearothermophilus*, revealed a homodimeric enzyme with each monomer consisting of an α/β barrel domain at the N-terminus and a C-terminal domain composed mainly of β strands. The active site is located at the interface of the α/β barrel and β domain near a PLP cofactor forming an internal aldimine linkage to a lysine residue [21,22]. Structural studies performed in the presence of substrate analogs have identified the residues involved in catalysis and shed light onto the enzyme's catalytic mechanism [23]. Moreover, structures of *G. stearothermophilus* alanine racemase with the covalent inhibitors

alanine phosphonate and D-cycloserine (DCS) have shown that enzyme inhibition is due to the covalent link of these compounds to the PLP cofactor and helped explain their non-specific inhibition of eukaryotic PLP-containing enzymes [24,25].

Alanine racemase structures from the human pathogens *Pseudomonas aeruginosa* and *Mycobacterium tuberculosis* have been solved [23] and both revealed further insights into the enzyme's catalytic site that may lead to identification of new, more specific inhibitors. The high-resolution (1.45 Å) structure of alanine racemase (DadX) from *P. aeruginosa* showed evidence for an external aldimine linkage of an unanticipated guest substrate in the active site [23], while the *M. tuberculosis* structure revealed that the narrow entryway to the enzyme's active site is composed of highly conserved residues distributed in layers beginning at the PLP site [26]. The structure of the DCS-producing *Streptomyces lavendulae* has also been determined [27]. *S. lavendulae* can grow in the presence of DCS, and the structural basis for the slower inhibition rate of DCS on *S. lavendulae* Alr has been attributed to the enzyme's larger and more rigid active site [27].

Here we report the cloning and characterization of the two genes, *dal1* and *dal2*, from the *B. anthracis* genome with sequence similarities to other bacterial alanine racemase genes. Although expression of *dal2* in a heterologous system failed, we have successfully expressed and purified the gene product of *dal1*, which we term $\text{Alr}_{\text{Bax}'}$ and performed its kinetic and structural characterization.

Recently another group has reported that *B. anthracis* alanine racemase crystallization required reductive methylation [28]. Interestingly we have not found this to be the case. However, the availability of both structures, one with and one without methylation, allows for a careful comparison to be performed. Reductive methylation has been employed previously to obtain atomic structures for proteins recalcitrant to crystallization [29-33]. Due to its reported successes, this method is becoming more utilized [28,34,35]. Nevertheless, there may be concerns as to how methylation impacts protein structure. Our analyses of both structures suggest that despite differences in space group and crystal lattice, reductive methylation does not significantly alter the structure of alanine racemase from *B. anthracis*.

Results and Discussion

Sequence analysis of the *Bacillus Dal* proteins

The sequences for both *dal1* and *dal2* genes amplified in our laboratory from *B. anthracis* (Ames) genomic DNA are 100% identical to those previously deposited in GeneBank (*dal1* GeneID: [1087014](#) and *dal2* GeneID: [30262102](#)) [36]. The protein sequences encoded by *dal1*

and *dal2* both contain the characteristic motifs expected for members of the alanine racemase family, such as a PLP-binding site near the N-terminus, the two key conserved catalytic amino acid residues Lys41 (Alr_{Bax} numbering) and Tyr270, and a set of conserved residues making up the entrance corridor to the alanine racemase active site [26] (Figure 1). The gene product of *dal1*, which we term Alr_{Bax}, is identical to the alanine racemase protein previously associated with germination in *B. anthracis* spores [37] and shares 57% amino acid identity with Alr_{Gst}. Dal2, on the other hand, shows 41% sequence identity to Alr_{Bax} and 40% identity to Alr_{Gst}.

Complementation analysis

In order to confirm that both *dal1* and *dal2* genes encode functional alanine racemases we expressed these genes in a D-alanine auxotrophic strain of *E. coli*, MB2795 [38]. Expression of the *dal1* gene from *B. anthracis* or *dadX* from *P. aeruginosa* fully restored the wild-type phenotype. Cells

transformed with pET28-TEV failed to grow, as did those transformed with the *B. anthracis dal2* gene (data not shown).

Overexpression, purification and biochemical characterization of Dal proteins

We used strain BL21(DE3), pLysS of *E. coli* to express *dal1* and *dal2* recombinant gene products. While *dal1* was expressed successfully, the expression of *dal2* failed repeatedly, even when conditions such as temperature, IPTG concentration, or strain background were changed (data not shown). Sequencing of the plasmid construct revealed no obvious errors, and our expression system has been successfully used for numerous proteins in the past. We have no conclusive explanation for our inability to express *dal2* at measurable levels in *E. coli*. While the *orf* appears to encode an alanine racemase enzyme, it clearly is not expressed in the T7 overexpression system, possibly also explaining the lack of complementation observed in




Figure 1
Structure-based alignment of alanine racemases from *B. anthracis* (AlrBax), *G. stearothermophilus* (AlrGst), *M. tuberculosis* (AlrMtb), *S. lavendulae* (AlrSla) and *P. aeruginosa* (DadXPao). The initial alignment was performed using EXPRESSO (3DCoffee) [63] and adjusted manually upon inspection of the superimposed structures. An asterisk marks the location of the Lys residue bound to PLP, the diamond marks the location of the Tyr residue that functions as the second base in the racemase reaction, a bullet denotes the location of the carbamylated lysine found in other alanine racemase structures and replaced by a chloride ion on Alr_{Bax}. I and M denote residues found in the middle or the inner layer of the active site entryway along with their position in the entryway.

our earlier experiments. Given that, to our knowledge, there are no reports characterizing *dal2* in the literature, we are led to believe that this gene is not usually expressed in its homologous host. As overproduction of *Dal2_{Bax}* failed, all subsequent work was performed with *dal1* to yield a product, which we term *Alr_{Bax}*. *Alr_{Bax}* was purified to homogeneity and displayed a single peak on molecular sieve chromatography.

Previous studies have suggested *Alr_{Bax}* might exist partly as a tetramer in solution [34]. We have used dynamic light scattering (DLS) to determine that *Alr_{Bax}* has a hydrodynamic radius of 3.7 nm, corresponding to a molecular weight of 93 kDa. As the calculated molecular weight of *Alr_{Bax}* is 43.7 kDa, this enzyme is unambiguously a dimer (ca. molecular weight 87.4 kDa) in solution under the conditions of this experiment. These measurements were made on a monodisperse solution of *Alr_{Bax}* in which 99.9% of the mass was accounted for by the single peak at 3.7 nm.

We find that purified *Alr_{Bax}* has a K_m for D-alanine of 2.8 mM and a V_{max} of 101 U mg⁻¹, where one unit was defined as the amount of enzyme that catalyzed racemization of 1 μmol of substrate per minute. These kinetic parameters for racemization of L- to D-alanine of *Alr_{Bax}* fall in the range of what has been observed before for other bacterial alanine racemases [38-40]. Interestingly, despite the high identity levels observed for residues in the active site of *Alr_{Bax}* and *Alr_{Gst}* (Figure 1), the V_{max} for the anthrax enzyme is one order of magnitude lower than the one reported for the *G. stearothersophilus* enzyme and closer to that observed for alanine racemases isolated from other pathogenic organisms. Our kinetic characterization reinforces previous observations that there is a very wide dynamic range in kinetic constants for alanine racemase, despite the sequence and structural similarities of their active sites.

Description of the Overall Structure of *Alr_{Bax}* from *B. anthracis*

Consistent with other alanine racemases, the tertiary structure of *Alr_{Bax}* is a homodimer formed by head-to-tail-association of two monomers (Figure 2). Each monomer is crystallographically distinct in this crystal form (Table 1), but the two monomers have very similar folds. The rms difference obtained for their C_α atoms after least-squares superposition is 0.22 Å. *Alr_{Bax}* monomers consist of two structurally distinct domains. Residues in the N-terminus (16–245) fold into an eight-stranded α/β barrel, while the C-terminal residues (246–389) and the first 15 N-terminal amino acids are part of a predominantly β-structure. The homodimer displays two active sites, formed by residues from the N-terminus of one monomer and residues from the C-terminus of the other monomer. The PLP cofactor forms a covalent bond to Lys41 and

points at the center of the α/β barrel. As previously observed for *Alr_{Gst}* [22], extra density was present in the active of *Alr_{Bax}*, which we model here as a molecule of acetate.

Structural comparisons of *Alr_{Bax}* with closely related enzymes

Below we compare *Alr_{Bax}* to the highly active *Alr* from the non-pathogenic bacterium *G. stearothersophilus* (*Alr_{Gst}*) as well as the less active *Alrs* from pathogenic bacteria *P. aeruginosa* (*DadX_{Pao}*) and *M. tuberculosis* (*Alr_{Mtb}*). We also compare *Alr_{Bax}* to the *Alr* from the DCS-producing bacteria *S. lavendulae* (*Alr_{Sla}*). These enzymes share between 26 and 57% sequence identity (Figure 1 and Table 2). The crystal structure of native *Alr_{Bax}* reveals some structural features that may be responsible for its slower catalytic rate and suggests regions that might be targeted in designing inhibitors of this enzyme.

As noted, the *B. anthracis* *Alr_{Bax}* secondary structure and general fold closely resembles that seen for other alanine racemases [23]. However, there are a few small topological differences between the structures of *Alr_{Gst}* and *Alr_{Bax}*. *Alr_{Bax}* is five residues longer than *Alr_{Gst}*; three of the five extra residues in *Alr_{Bax}* extend Helix 8 by one turn; while the remaining two extra residues locate to the very N-terminus of *Alr_{Bax}*. Helix 8 does not take part in the enzyme's active site nor does it make intermonomer contacts, therefore, we do not anticipate this secondary structure to play a critical role in *Alr_{Bax}* function.

Least-squares superposition of C_α atoms from N- and C-terminal domains from *Alr_{Gst}*, *Alr_{Sla}*, *Alr_{Mtb}* and *DadX_{Pao}* to the equivalent domains in *Alr_{Bax}* reveals average rms differences ranging from 1.10 to 2.30 Å. The rms differences correlate with sequence identity levels (Table 2). Superposition of the N-terminal domains of *Alr_{Bax}* and *Alr_{Gst}* reveals significant C_α deviations (≥ 1.8 Å) for residues in three loops (residues 121–125, between H6 and S6; residues 198–202, between H8 and S8; residues 215–219, between H9 and S9) and residues 148–158 on H7. These regions all locate to the protein surface and have no reported role in homodimer formation or substrate binding and catalysis. On the other hand, superposition of the C-terminal domains of *Alr_{Bax}* and *Alr_{Gst}* shows no regions with C_α rms differences greater than 1.4 Å.

***Alr_{Bax}* and *Alr_{Gst}* have a similar hinge angle between N- and C-terminal domains**

The overall rms differences among various bacterial alanine racemases (Table 2) suggest that despite their topological similarity there are notable structural differences between their individual domains. It has been reported previously that the hinge angle between N- and C-terminal domains varies among different alanine racemases [23]. It is due to this difference that monomers from dif-

Table 1: Data-collection and structure-refinement statistics.

Data collection	
Space group	P2 ₁
Unit-cell parameters	a = 49.62 Å, b = 141.27 Å, c = 60.12 Å α = γ = 90.00°, β = 103.11°
Observations	150,355 (12,217)
Unique reflections	53,396 (5,695)
Resolution (Å)	32.79–1.95 (2.06–1.95)
Completeness (%)	91.3 (67.1)
R _{merge} (%)	2.9 (15.6)
Mean (I)/σ(I)	22.2 (5.4)
Redundancy	2.8 (2.1)
Refinement statistics	
Resolution (Å)	32.79–1.95 (2.01–1.95)
Reflections	51,760 (2,518)
Total atoms	6,436
R _{work} (%)	16.0 (19.40)
R _{free} (%) (for 1627 reflections)	20.1 (23.4)
Average B factor (Å ²)	
main chain	34.7
side chain	36.6
PLP	29.7
RMS deviations	
bond length (Å)	0.017
bond angles (deg.)	1.46
no. of residues	772
no. of protein atoms	6038
no. of PLP atoms	30
no. of acetate atoms	8
no. of water atoms	358
no. of chloride ions	2

Values in parentheses are for the highest resolution shell.




Figure 2
Ribbon representation of the dimer of the alanine racemase from *B. anthracis*. The PLP co-factor is shown as a ball and stick model. Monomers are shown in different colors. N and C indicate the position of the C- and N-termini of one monomer; primed letters denote the termini for the second monomer.

ferent alanine racemases cannot be optimally superimposed onto each other as a whole. While a single hinge angle comparison was sufficient for the pair-wise analysis previously given, the inclusion of more racemase structures has let us to consider a new system of hinge angle description. In this system, following superposition of the N-terminal domains, we define the shift in the C-terminal domains of one racemase compared to another through two rotation angles. One is measured relative to a plane parallel and one relative to a plane perpendicular to the PLP ring (Figure 3). The hinge rotations relative to the N-terminal domain may be relevant for enzyme activity as it could influence the position of the second catalytic residue, Tyr270' (primed numbers denote residues found in the second monomer). For the planes parallel and perpendicular to the PLP ring the rotation for the C_α atom of Tyr270' from Alr_{Bax} compared to the structurally equivalent atom in Alr_{Gst}, Alr_{Mtb}, Alr_{Sla} and DadX_{Pao} is 0.4/2.7°, 3.9/8.2°, 8.7/2.3° and 10.3/5.9°, respectively (Figure 3). Given that Alr_{Gst} and Alr_{Bax} have the most similar hinge angles we have compared these two structures with the

other Alrs in order to establish which regions are responsible for the hinge angles in various Alrs.

Differences in hinge angles between various Alrs were first reported by us for Alr_{Gst} and DadX_{Pao} and attributed to specific polar interactions present only in Alr_{Gst}. These interactions are mediated by polar side chains of residues Asp68 and Arg89 of the first Alr_{Gst} monomer and the polar side chain of Asn379 and main chain O from Phe4 and main chain N from His5 of the second monomer [23]. Here in Alr_{Bax} we find equivalent polar interactions facilitated by structurally analogous residues; Asp70 and Arg93 of the first Alr_{Bax} monomer and Phe6, Tyr7 and Asn384 of the second monomer. An additional interaction takes place between Asp77 from Helix 4 and Leu386 and Ile389 in Alr_{Bax}. Therefore, the polar contacts that have been proposed to mediate the hinge angle in Alr_{Gst} are also present in Alr_{Bax} and as noted above these two structures have the most similar hinge angles. On the other hand, these polar contacts are not seen for Alr_{Mtb}, Alr_{Sla} and DadX_{Pao}. Figure 4 shows that the side chains of residues in Alr_{Bax} taking part in intra-monomer interactions make extensive contacts with residues on the second monomer, when compared with structurally equivalent residues in Alr_{Sla}, Alr_{Mtb}, Alr_{Sla} and DadX_{Pao} are shorter than Alr_{Gst} and lack structurally equivalent residues to the C- and N-terminus of the longer enzymes (Figure 1). For example, Alr_{Sla} has no analogous residue to Asn384 in Alr_{Bax} as the peptide chain is only 380 residues long. Moreover, the structurally equivalent residue for the polar arginine is Gly89. It is not surprising that the hinge angles of these three deviate most from Alr_{Gst}.

This analysis notwithstanding, the relevance of the hinge angle to enzyme catalysis in alanine racemase remains unclear. Although the V_{max} values reported for all alanine racemases studied to date vary by over three orders of magnitude, it is not straightforward to attribute these differences to hinge angle. Differences in hinge angles certainly alter the relative orientation of the two active sites in the dimer, but affect very little the geometry of each active site as indicated in Table 2. Further, the V_{max} for Alr_{Gst} and Alr_{Bax} enzymes varies by more than 10 fold, despite having similar hinge angles. Altering the hinge

Table 2: Average r.m.s.d. (Å) between the C_α atoms of Alr_{Bax} and other Alrs

Alanine Racemase	Whole monomers ^a	N-terminal domains ^b	C-terminal domains ^c	Active site ^d
Alr _{Gst}	1.10 (57%)	1.07 (57%)	0.60 (59%)	0.45 (73%)
Alr _{Sla}	1.71 (37%)	1.66 (36%)	1.12 (39%)	0.73 (51%)
Alr _{Mtb}	1.84 (39%)	1.64 (36%)	1.11 (40%)	0.83 (44%)
DadX _{Pao}	2.30 (26%)	1.82 (26%)	1.43 (32%)	0.81 (41%)

Numbers in parenthesis denote sequence identity with Alr_{Bax}. ^aCalculated using monomer A. ^bCalculated using residues 4–245. ^cCalculated using residues 246–389. ^dCalculated using residues 39–45, 63–67, 84–88, 103–107, 127–140, 163–171, 203–210, 221–228, 356–363 from monomer A and 268–271 and 314–319 from monomer B.



Figure 3
Differences in hinge angle between various alanine racemases. Structural alignment of the N-terminal domain α/β barrel from *B. anthracis* (green), *G. stearotherophilus* (red), *M. tuberculosis* (pink), *S. lavendulae* (blue) and *P. aeruginosa* (yellow) shows that the hinge angle between N- and C-terminal domains can vary. N- and C-termini are labeled N and C and colored according to their respective structures. The PLP cofactor for Alr_{Bax} is shown as a ball and stick model in black.

angle of this enzyme experimentally through mutation or cassette swapping may resolve this issue.

Intermonomer contacts and surface area

The dimer interface in alanine racemase is an important area for structural analysis. Only the dimeric form of the enzyme is catalytically active [41]. Therefore, interface residues are critical in forming a functional active site. Certainly the interface functions to correctly position the second catalytic tyrosine residue from the opposite monomer on top of the active site. In addition, both monomers contribute to the overall composition of the alanine entryway and binding pocket. Loss of interface contacts would alter this arrangement and could be used as a strategy to inhibit Alr activity. Disruption of dimer interfaces is becoming more common and has been successfully used recently for drug targets in HIV and HCV [42-44].

Despite large differences in hinge angles, the location of interface residues in various Alrs is very similar (Figure 5). In Figure 5, the $\text{C}\alpha$ atoms for residues taking part in intermonomer contacts in various Alrs are shown as colored spheres. The positions for the various spheres were obtained following two independent structural alignments, one using only atoms from the N-terminal domain and the other using only atoms from the C-terminal domain, and then plotted onto a ribbon diagram of Alr_{Bax} . If the position of residues taking part in intermonomer

contacts is conserved among various Alrs, we would expect the colored spheres to form tight clusters, containing superimposed red, green, blue, yellow and pink spheres. Indeed, as shown in Figure 5, most of the intermonomer contacts from various Alrs are found in clusters and thus are conserved among various Alrs. It is important to keep in mind that the number of residues taking part in intermonomer contacts varies among the analyzed Alrs. For Alr_{Bax} , 94 of its 389 residues take part in intermonomer contacts and both N- and C-terminal domains contribute an almost equal number (44 and 50, respectively) of residues to the interface. The total number of residues in the interface of Alr_{Gst} , Alr_{Mtb} , Alr_{Sla} and DadX_{Pao} is slightly smaller than in Alr_{Bax} . Nevertheless, for all analyzed structures, both domains contribute almost equally to the monomer-monomer interface.

At its dimer interface, the Alr_{Bax} structure displays a larger surface area and higher number of polar interactions than Alr_{Gst} , Alr_{Sla} and DadX_{Pao} (Table 3). Not surprisingly, most of the additional buried surface area observed for Alr_{Bax} results from the interactions involving N- and C-terminal residues described in the hinge angle analysis above. If residues from the N-terminus (4-10) and C-terminus (383-389) of Alr_{Bax} are excluded from the calculation, the intermonomer surface area of Alr_{Bax} is reduced from 3,500 to 2,500 \AA^2 , making it similar to the values found for Alr_{Sla} and DadX_{Pao} ($\sim 2700 \text{\AA}^2$) (Table 3).

Alr_{Bax} PLP-binding and active site

As observed for other Alrs, the active site of Alr_{Bax} is formed by residues from both monomers, with the two catalytic bases Lys41 and Tyr270' found in different monomers. In the Alr_{Bax} structure, Lys41 is seen covalently linked to the PLP cofactor. As was observed for one of the Alr_{Gst} structures (1sft) [22], we have identified extra density in the active site of Alr_{Bax} which we have modeled as a molecule of acetate. Acetate, which was present in our crystallization solution, is an inhibitor of Alr [22] and its carboxylate group is thought to bind the enzyme active site in the same way the carboxylate group from alanine is expected to do [22]. The oxygen atoms from the acetate molecule in our model are within hydrogen bonding distance to the side chain oxygen from Tyr289', the main chain nitrogen from Met317' and, perhaps more importantly, to the side chain nitrogen atom from the catalytic Lys41 residue (Figure 6).

The identity and position of active site residues is strongly conserved among various Alrs (Table 2). As a result, the hydrogen bonding network found for the PLP molecule in the active site of Alr_{Bax} is similar to the one observed for other Alrs. In Alr_{Bax} , side chain atoms from Tyr45, Arg138, Arg24, His168, Ser209 and Tyr359 establish hydrogen bonds to atoms in the PLP cofactor (Figure 6). These resi-




Figure 4
Molecular surface for one monomer of the alanine racemases from *B. anthracis* (A) and *S. lavendulae* (B) docked into the ribbon diagram of the opposite monomer. Alr_{Bax} has extended intermonomer contacts at its C- and N-termini that are not present for other alanine racemases like the one from *S. lavendulae*. Position of residues taking part in intermonomer contacts are shown in purple and yellow for Alr_{Bax} and green and red for Alr_{Sla} . For Alr_{Bax} , residues on Helices 4 and 5 and on N- and C- termini that make intermonomer polar contacts are shown as sticks. Equivalent residues taking part in intermonomer contacts are also shown as sticks for Alr_{Sla} . Positions for the N- and C- termini, Helix 4 and Helix 5 are indicated by arrows.

dues are strictly conserved for Alr_{Cstr} , Alr_{Mtb} , Alr_{Sla} and $DadX_{PaO}$ and have similar orientations in the PLP-binding site of their respective enzymes. The PLP in Alr_{Bax} also hydrogen bonds with main chain atoms from Ser209, Gly226 and Ile227. The first two of these residues is strictly conserved in Alr_{Cstr} , Alr_{Mtb} , Alr_{Sla} and $DadX_{PaO}$. The third would be as well but in Alr_{Sla} the Ile227 is replaced by a leucine residue. Perhaps a more significant difference is the presence in Alr_{Sla} and Alr_{Mtb} of a tryptophan residue in place of Alr_{Bax} Leu87. A tryptophan residue at this position is one of the differences found between the active sites of the slower enzymes from *M. tuberculosis* and *S. lavendulae* and the faster Alr from *G. stearothermophilus*. In Alr_{Sla} and Alr_{Mtb} the N ϵ atom of this tryptophan makes a water-mediated hydrogen bond to O3 from PLP. Although this extra interaction may have a role in catalysis it does not seem to reduce the size of the Alr_{Sla} and Alr_{Mtb} active sites as the loop that harbors this tryptophan residue is shifted away (~ 2.1 Å) from the PLP cofactor when compared to the same loop in Alr_{Bax} . Mutagenesis studies

could thus be performed in order to evaluate the impact of this tryptophan residue for enzyme catalysis.

One striking difference in the active site involves Asn131, which in other alanine racemases is generally a carbamylated lysine that participates in a hydrogen bond with the residue homologous to Arg138. In Alr_{Bax} , however, we note a prominent chloride ion that is located near Arg138 in the active site (Figure 6). This chloride ion has not been described in Alr structures from other species and it was originally modeled by us as a water molecule. However, the resulting low B-factor (~ 10 Å²) and its hexacoordination with three water molecules and atoms N δ 2 from Asn131 and N ϵ and N η 2 from Arg138 suggested the presence of a chloride ion. Notably, there is no chloride present in the crystallization buffer and we can only assume that the enzyme binds so tightly to this halide that it is carried over from the enzyme's purification. The chloride ion is also observed on the Alr_{Bax} structure obtained following lysine reductive methylation [30]. The presence of a chloride ion in two independent structures reinforces




Figure 5
Position of residues taking part in intermonomer contacts is highly conserved among various Alrs, despite differences in hinge angles. Following a structural alignment of the N-terminal domains of various Alrs, the position for the C α atoms from residues that take part in intermonomer contacts and are in the N-terminal domain (shown as colored spheres) was plotted on the main chain representation of Alr_{Bax} (shown in green). Likewise, the position for the C α atoms from residues that take part in intermonomer contacts and are at the C-terminal domain (shown as colored spheres) were plotted on the main chain representation of Alr_{Bax} after a structural alignment of the C-terminal domains of various Alrs. Residues are colored according to the legend on figure 3. The PLP cofactor from Alr_{Bax} is shown as a ball and stick model. N and C indicate the position of the C- and N-termini in the monomer.

the idea that this ion plays an important structural role in Alr_{Bax}. Other Alrs have a negative charge at the same position, but the charge has always been from a carbamylated

lysine residue (Figure 6). In the Alr_{Mtb} structure a carbamylated lysine was not noted but the side chain density for this lysine was poor. Like the chloride ion in Alr_{Bax}, the carbamyl group found in other Alrs hydrogen bonds with N ϵ and N η 2 from the active site arginine (Arg138 in Alr_{Bax}), thus positioning this residue in the active site. The general conservation of the modified lysine residue among various Alrs and its role in positioning the active site arginine indicates that the presence of a negative charge at this position is critical for enzyme catalysis. As Alr_{Bax} lacks the conserved lysine residue necessary for carbamylation it has apparently drafted a chloride ion to fill the same role for this species. It is open to speculation whether the addition of chloride chelators like SPQ (6-methoxy-N-(3-sulfopropyl)-quinolinium) would affect the enzyme activity and whether it might be possible to design specific inhibitors for Alr_{Bax} based on this unique interaction.

In Alr_{Bax} in addition to the interactions facilitated by the chloride ion, Arg138 is further positioned by the side chain oxygen of Thr316'. Further, an alignment of 105 Alrs, having between 24% to 99% sequence identity to Alr_{Bax}, revealed that the presence of an asparagine at the equivalent position to Asn131 in Alr_{Bax} is always accompanied by the presence of a threonine residue equivalent to Thr316' (data not shown) suggesting that this interaction with Arg138 would be a conserved feature of alanine racemases with active site structural chlorides. Sequences of Alrs that contain a lysine in position 131 almost always have an accompanying serine or a cysteine residue in position equivalent to Alr_{Bax} Thr316'. In the case of Alr_{Pao} this serine is involved in an equivalent active site arginine interaction. The exception to this latter observation is Alr_{Sla} which has an alanine at this position. It is important to note that there is not really a specific chloride-binding motif as the residues that interact with Cl⁻ in Alr_{Bax} are the same that interact with the carbamylated lysine in the other structures.

The active site entryway of Alr_{Bax}

Residues from loops in the α/β barrel domain of one monomer and residues from the C-terminal domain of the second monomer make up an entryway to the active site and the PLP binding site. The active site entryway of Alr has been previously divided in inner, middle and outer layers, starting from the PLP binding pocket and moving towards the protein surface [26]. Residues in the inner and middle layers show strong conservation among various Alrs [26]. For Alr_{Bax}, residues Tyr270', Tyr359, Tyr289' and Ala172 constitute the inner layer, while residues Arg314', Ile357, Arg295' and Asp173 make up the middle layer. These residues are absolutely conserved between Alr_{Bax} and Alr_{Gst'}, Alr_{Mtb}, Alr_{Sla} and DadX_{Pao}. The outer layer for the active site entryway of various Alrs displays less conservation, but in this region Alr_{Bax} contains

Table 3: Intermonomer interactions for alanine racemases


alanine racemase	Intermonomer surface area (Å ²)	hydrogen bonds	salt bridges
Alr _{Bax}	3536	38	9
Alr _{Gst}	3083	31	12
Alr _{Sla}	2798	20	7
DadX _{Pao}	2788	14	7

an Asn271' while Alr_{Gst}, Alr_{Mtb}, Alr_{Sla} and DadX_{Pao} contain a glycine. As a result of this substitution, the entryway is somewhat more restricted than the ones observed for other alanine racemases. Finally, for Alr_{Bax} a conserved pair of acidic residues (Asp-Glu) is found at positions 173 and 174, which are located in the middle and outer layers of the entryway. Identical residues are found in the same position for Alr_{Gst}, Alr_{Sla} and DadX_{Pao}, but for Alr_{Mtb} a much slower alanine racemase, these two residues are (Asp-Lys). This site has recently been shown to be important catalytically, as making this Asp-Glu to Asp-Lys

change at the same position in *E. coli* alanine racemase has been shown to significantly decrease its catalytic rate [45].

Structural comparison of native and reductively methylated alanine racemases from *B. anthracis*

Recently, the structure of Alr_{Bax} after reductive methylation of its lysine residues (Alr_{BaxRM}) has been reported [28]. In that report, the unmodified protein failed to crystallize. Scientists at the Oxford Protein Production Facility (OPPF) and the York Structural Biology laboratory reported that extensive crystallization trials (approximately 800 conditions) with native Alr_{Bax} proved unsuc-

**Figure 6**

Organization of the active site residues in *B. anthracis* Alr is facilitated by a chloride ion. (A) Electron density map (contoured at 1.5σ in the final refined $2F_o - F_c$ map) showing details of the active site for Alr_{Bax}. (B) Structural alignment of residues making the active site of various Alrs (TB structure was not included). For all available Alr structures, Arg138 makes polar contacts to the PLP and, possibly, to the substrate. In Alr_{Bax} this arginine residue is positioned in the active site by a chloride ion (Cl⁻). Polar contacts between the chloride ion and Asn-131 and Arg-138 are shown in Panel A by dashes. For all other alanine racemase structures available to date the equivalent interactions are mediated by a carbamylated lysine (shown in Panel B). Residues in the active site of various Alrs are shown as a stick model. In Panel A, the acetate molecule and the modified lysine residue (LLP) are depicted as ball and stick models; carbons are colored in green, nitrogen in blue, oxygen in red, phosphate in orange, sulfur in yellow and the chloride ion is depicted as a light green sphere. In Panel B residues are shown as stick model and are colored according to the legend on figure 3; the PLP cofactors are shown as ball and stick models. In both panels, primed numbers denote residues from the second monomer.

cessful and that reductive lysine methylation was essential for crystallization of the protein [34,46]. Based on data from mass spectroscopy and on the methylated crystal structure of Alr_{Bax} , Au and colleagues concluded that the N terminus and 18 out of the 20 lysines in Alr_{Bax} were methylated after the protein was treated with dimethyl-amine-borane complex and formaldehyde.

Reductive methylation modifies all free primary amines in a protein molecule (NH groups from lysine residues and the N terminus) to tertiary amines. This modification of lysine residues, especially those found on the protein surface, offers an opportunity to change a protein's crystallization properties and is a proven method to rescue proteins recalcitrant to crystallization [28-33,35,47]. However, there are few structural studies showing that reductive alkylation does not alter a protein's structure, especially of proteins that do not readily crystallize. One study [48] reporting on the effects of reductive lysine methylation on HEW lysozyme found that crystals were formed under different conditions and with a different crystalline lattice than observed for the unmodified enzyme. Nevertheless, the structures of both modified and unmodified enzymes showed no significant structural differences and their superimposed $\text{C}\alpha$ atoms had an rms difference of only 0.4 Å [48]. The availability of native and modified structures for Alr_{Bax} , therefore, offers another opportunity to evaluate the impact of reductive lysine methylation, this time on a protein more recalcitrant to crystallization.

In our hands, Alr_{Bax} protein readily formed small crystals using commercially available crystallization screens. Notably our form contains eight additional residues at the C-terminus that remain following cleavage of a C-terminal His-tag using TEV protease. These residues are not involved in crystal contacts, but still could have an influence on crystallization. Our initial crystallization conditions required extensive fine-tuning, and the addition of the glutathione additive proved important for obtaining diffraction quality crystals. Moreover, finding the proper conditions for freezing Alr_{Bax} crystals without compromising diffraction quality proved challenging. For simplicity's sake we have referred to this form of Alr_{Bax} as unmethylated or native. Our review of the expression and purification protocols for both native and alkylated enzymes suggests that they were very similar. Also, modified and unmodified Alr_{Bax} crystallize under similar conditions, despite a reported small reduction in the isoelectric point and the expected changes in the surface properties of Alr_{Bax} [34]. Both proteins were crystallized in the presence of PEG (18% PEG 8000 for the native and 25% PEG 3350 for the modified protein), high salt concentrations (0.2 M sodium acetate for the native and 0.2 M magnesium chloride for the modified protein) and at the same pH, 6.5.

Interestingly, the modified enzyme was crystallized at 60 mg/ml while the native structure was obtained from crystals grown at 15 mg/ml.

Despite similar crystallization conditions native and modified Alr_{Bax} crystals show different crystalline lattices and solvent content. Native Alr_{Bax} crystals are monoclinic with space group $\text{P}2_1$ and unit cell parameters $a = 49.6$ Å, $b = 141.3$ Å, $c = 60.1$ Å and $\beta = 103.11^\circ$. On the other hand, crystals for the methylated enzyme are orthorhombic in space group $\text{P}2_12_12_1$ with cell dimensions of $a = 57.6$ Å $b = 88.4$ Å and $c = 139.0$ Å. Crystals for the modified enzyme display a lower solvent content (38% vs. 48%) and a higher packing density (1.99 Å³/Da vs. 2.35 Å³/Da) than native crystals.

Crystal contacts comparison

The total surface area found in crystal contacts for the reductively methylated enzyme is 1.7 times larger than that found for the native enzyme (1529.7 Å² vs. 918.4 Å², respectively). Further, these contacts are often mediated by methylated lysine residues found at the protein surface (Figure 7). In monomer A from $\text{Alr}_{\text{BaxRM}}$, 6 out of the 18 modified lysines contact protein atoms from both monomers in adjacent asymmetric units. For monomer B, 9 modified lysines engage in crystal contacts; contacting




Figure 7
Difference in crystal contacts following reductive methylation of secondary amines on Alr_{Bax} . The position of $\text{C}\alpha$ atoms from residues making crystal contacts are shown as colored spheres superimposed onto the ribbon diagram of Alr_{Bax} (shown in green). Methylated lysines involved in crystal contacts are shown in red; other residues involved in crystal contacts for the methylated structure only are shown in yellow. Residues implicated with crystal contacts for the native structure only are shown in blue. Residues found to make crystal contacts in both structures are shown in green. N and C indicate the position of the C- and N-termini of one monomer; primed letters denote the termini for the second monomer.

protein atoms in both monomers from symmetry related protein molecules. Interestingly, methylated lysine 202 from monomer A contacts the same residue from monomer B in a symmetry related molecule. In Figure 7, the location of the C α atoms from residues taking part in crystal contacts for both the native and methylated structure is shown as colored spheres. Different colors were used for various categories of contacts. Yellow and red spheres are for contacts observed only in crystals of the methylated protein, while blue spheres are found only in the crystals of the native protein. Contacts found in both crystal forms are shown as green spheres. Figure 7 illustrates that crystals of the methylated Alr_{Bax} contain more residues taking part in crystal contacts, and as noted above, modified lysine residues, shown as red spheres, make many of these crystal contacts. In this case of Alr_{Bax} reductive methylation does change the protein surface in a way to promote the formation of a more extensive and apparently more ordered crystalline lattice than that found for the native crystals.

The surfaces of the modified and native Alr_{Bax} crystals are also different in terms of metal and halide content. Four magnesium and three chloride ions were found on the surface of modified Alr_{Bax} and take part in crystal contacts. For the native Alr_{Bax} structure we did not identify any metal or halide ions at equivalent positions. Furthermore, the temperature factors for these surface ions are quite low, with four less than 20 Å², and many are involved in extensive electrostatic interactions. Perhaps the presence of additional metal ions observed exclusively for the methylated crystal form of Alr_{Bax} acts to compensate for the loss of positive charges at the protein surface.

Most importantly, reductive methylation did not alter the overall fold of Alr_{Bax}. Structural alignment of methylated and native Alr_{Bax} shows no significant difference in their overall structures. For the individual monomers the rms difference between their C α atoms is just under 0.4 Å. Alignment of the active site residues from the two Alr_{Bax} structures shows that reductive alkylation of the enzyme did not result in any significant changes in the position and hydrogen bond pattern of active site residues and the PLP co-factor. Moreover, the hinge angle between N- and C-terminal domains is very similar for both modified and unmodified Alr_{Bax}. Thus, the hinge angles observed for Alr_{Bax} are inherent to this particular enzyme and not an artifact of crystallization. As an aside, this observation makes a strong argument that the disparate hinge angles observed for other Alrs are not a consequence of divergent crystal packing.

Reductive methylation also did not significantly alter the dimer interface, which is found to be comparable between methylated and unmethylated structures (3600 Å² vs.

3500 Å², respectively). For the modified structure, two methylated lysines contribute atoms from their methyl groups to the interface; Mly182 and Mly255. The corresponding lysines in the native structure are not considered to be part of the interface; Lys182 displays poor density and did not have its complete side chain modeled in the native structure and no atoms from Lys255 in one monomer are in contact distance to atoms in the other monomer.

Only two lysines escaped methylation in the modified crystal structure, Lys41 and Lys260 [46]. Lys41 is found covalently bound to the PLP co-factor. Thus its NH group is not a primary amine and is not surprising that this residue is unaffected by the reductive methylation protocol. Lys260 is the lysine residue least exposed to the solvent and it makes hydrogen bonds to Gly137 and Arg138 which, in turn, hydrogen bonds to the phenolic oxygen of the PLP cofactor and to the substrate (see above). These two residues are, therefore, involved in either a covalent bond or a strong polar interaction in the present structure and thus predictably escaped reductive methylation.

Conclusion

In conclusion, we report the high-resolution crystal structure of alanine racemase from the *dal1* gene of *B. anthracis* and characterize it kinetically and in an *E. coli* complementation system. This structure contains some unique features in its active site including a structural chloride atom. It shares a similar hinge angle to its close relative from *Geobacillus* and has an active site and topology much like other members of this family. Based on the results shown here the active site of Alr_{Bax} is as accessible for inhibitor binding as other alanine racemases studied to date. Furthermore, it is very likely that alanine racemase inhibitors like D-cycloserine or alanine phosphonate will be effective as modulators of sporulation. Finally, as treatment of spores will take place in the environment and not internally, the problems associated with non-specific PLP inhibition ascribed to these inhibitors should not detract from their usefulness in bioremediation. We look forward to exploring more structural studies on these inhibitors as they become available.

Methods

Amplification and cloning of the *B. anthracis* *alr* genes

Two putative open reading frames, *dal1* and *dal2*, for alanine racemase from *B. anthracis* were identified through sequence comparisons using the known alanine racemase sequence from *G. stearothermophilus* [22] as a probe against the *B. anthracis* genome deposited in GenBank [36]. Two sets of primers were used in PCR to amplify the two putative *alr* genes from genomic DNA of *B. anthracis* (Ames), *dal1*-5' (5'-GGG GCC ATG GAA GAA GCA CCA TTT TAT CGT G-3')/*dal1*-3' (5'-CCC CCT CGA

GTA TAT CGT TCA AAT AAT TAA TTA C-3') and dal2-5' (5'-GGG GCA TAT GAG TTT GAA ATA TGG AAG AG-3')/dal2-3' (5' CCCCCTGCAGAAATCCGTAGGTTTTAAGGAC 3'), resulting in amplicons of 1169 bp and 1175 bp, respectively. The PCR products were sequenced, inserted into a modified pET28 vector (pET28-TEV) containing a C-terminal His-tag and a TEV protease cleavage sequence, LEENLYFQ/SLQVEH₆ and cloned in *E. coli* MB1547. (/) denotes the location of the cleavage site.

Complementation analysis

Characterization of the two cloned genes continued with their transformation into the D-alanine auxotrophic *E. coli* strain MB2795 [38]. A plasmid encoding the cloned *P. aeruginosa* DadX alanine racemase, pMB1921 [49], was used as a positive control. Plasmid pET28-TEV without any inserts served as the negative control. Cells were grown on solid LB medium with and without D-alanine supplementation, and scored for colony growth after 16 h at 37°C as described previously [49].

DalI overexpression and purification

Cultures of *E. coli* BL21(DE3), pLysS containing the pET28-TEV-dal expression plasmids were grown at 37°C in LB medium containing 100 µg/ml kanamycin and 30 µg/ml chloramphenicol to an OD₆₀₀ of 0.8. Expression of recombinant proteins was induced by addition of 0.5 mM IPTG and carried at 30°C for 19 hours. Cells were harvested by centrifugation and the cell lysate was cleared and loaded onto a Hi Trap affinity (Ni²⁺) column (GE Healthcare Life Sciences). The column was washed and Alr_{Bax} eluted with a stepwise imidazole gradient. The C-terminal 6xHis tag was removed by treatment with His-tagged TEV protease (1 mg TEV protease per 10 mg of protein for 16 hours at 4°C). Alr_{Bax} without the 6xHis tag was purified from the reaction mixture using the same chromatography strategy described above. Following concentration, Alr_{Bax} was loaded onto a Pharmacia Superdex 200 Preparative Grade column; sample purity was assessed by SDS-PAGE to be greater than 95%.

Dynamic light scattering

Purified Alr_{Bax} was dialyzed against 20 mM Tris pH 8.0. Protein samples (1 mg/ml) were centrifuged (10 min. at 14,000 rpm) and filtered using 0.02 µm Whatman Anotop filters prior to recording data. All measurements were made at 298 K using the DynaPro system according to the manufacturer's instructions (Wyatt Technology).

Enzyme Kinetics and Crystallization

The kinetic parameters (K_m and V_{max}) for the racemization reaction (D- to L-alanine) catalyzed by Alr_{Bax} were estimated using the spectrophotometric alanine racemase assay as described previously [40]. Alr_{Bax} crystallization screening trials were performed using the vapor diffusion method with sitting drops (5 µl of protein at 15 mg/ml

and 5 µl of mother liquor) in 24-well plates incubated at 4°C. Initial screens revealed thin needle crystals growing in 20% PEG 8000, 0.2 M sodium acetate, 0.1 M sodium cacodylate, pH 6.5 [50]. Crystals were optimized using streak-seeding with crushed crystals and further optimized using additive screening resulting in rectangular, deep yellow crystals suitable for data collection. The final crystallization condition was 18% PEG 8000, 0.2 M sodium acetate, 0.1 M sodium cacodylate, pH 6.5, 0.01 M GSH (L-glutathione reduced), 0.01 M GSSG (L-glutathione oxidized).

Data Collection and Processing

Crystals were passed through cryoprotectant solutions consisting of 20.7% PEG 8000, 0.2 M sodium acetate, 0.1 M sodium cacodylate supplemented with 3, 6, 9, 12, 15 and 18% (v/v) ethylene glycol, mounted into a nylon loop and flash frozen in liquid nitrogen at 110 K. A native data set was collected at 110 K on a Micromax 007 HF rotating-anode X-ray generator equipped with a copper anode, Hi-res optics, an RAXIS IV++ image-plate detector (Rikagu) using a frame width of 0.5° and an exposure time of 600 s. Images were integrated using MOSFLM [51], processed with SCALA [52] and analyzed using programs from the CCP4 suite [53]. Data collection and processing statistics for the native data set can be found in Table 1. Alr_{Bax} crystallized in space group P2₁ with unit cell parameters a = 49.62 Å, b = 141.27 Å, c = 60.12 Å and β = 103.11. There is one Alr_{Bax} dimer per asymmetric unit.

Structure Determination and Refinement

Molecular replacement was carried out with MolRep [54] using the *G. stearothermophilus* Alr (PDB entry – 1SFT) atomic coordinates [22]. Molecular replacement was performed assuming two monomers per asymmetric unit as suggested by a Matthew's coefficient of 2.35 [55] and resulted in the proper orientation of the search model in the crystal lattice (R_{fac} 43.6%; score 0.699). The primary sequence of the search model was changed to that of Alr_{Bax} using Coot [56]. All structural refinements (32.79 – 1.95 Å) were carried in Refmac5 [57] using standard restraints and were followed by visual inspection of protein models and density maps in Coot. Ten cycles of positional refinement, performed using NCS restraints, resulted in R and R_{free} of 23.9 and 27.2%, respectively. Waters were added using the arp_water function on Refmac5, and when the active site density was clearly interpretable, PLP was added to both active sites. A further 10 cycles of positional and B_{iso} refinements brought R and R_{free} to 19.6 and 23.7%, respectively. Water molecules with B-factors higher than 55.0 Å² and electron density lower than 1.0 σ on a $2F_{obs} - F_{calc}$ map were then deleted.

TLS Refinement

B. anthracis crystals displayed somewhat anisotropic x-ray diffraction and previous alanine racemase structures have

shown indication of subdomain movement. This encouraged us to try TLS refinement [58]. TLS analyses were carried on with different domains of the protein acting as a rigid body. All models resulted in similar improvements in R and R_{free} and in the end we adopted the most parsimonious one, which treated all protein atoms found in the asymmetric unit as a rigid body. After TLS refinement, the R and R_{free} were 16.0 and 20.1% with root-mean-square deviations from ideality for bond lengths of 0.017 and angles of 1.46° (Table 1). As noted above, inclusion of the C-terminal His-tag has resulted in eight additional residues in our sequence. In the final map we attempted to build some of these residues into extra density at the C-terminus, but as we did not gain anything in terms of R or R_{free} we have elected to leave out the extra residues from this region in the final structure. Structure factors and final atomic coordinates for Alr_{Bax} have been deposited in the Protein Databank (PDB ID [3ha1](#)).

Structural comparisons

The structure of Alr_{Bax} was compared to other closely related enzymes; their accession numbers are: [1sft](#) – Alr_{Gst} bound with acetate [22]; [1vfh](#) – Alr_{Sla} with no ligand [27]; [2vd8](#) – methylated Alr_{Bax} [28], [1rcq](#) – DadX_{Pao} [23] and [1xfc](#) – Alr_{Mtb} [26]. Structural alignments were performed using SSM [59]. Interface surface area was calculated using PISA [60]. The number of polar contacts (hydrogen bonds and salt bridges) was determined using WHAT IF [61,62].

List of Abbreviations

Alr: alanine racemase; Bax: *Bacillus anthracis*; DCS: D-cycloserine; Gst: *Geobacillus stearothermophilus*; Mtb: *Mycobacterium tuberculosis*; Pao: *Pseudomonas aeruginosa*; PLP: pyridoxal 5'-phosphate; rms: root mean square; Sla: *Streptomyces lavendulae*.

Authors' contributions

RC performed research, helped draft manuscript, analyzed results, and prepared figures. US performed research, helped draft manuscript, analyzed results. MD performed research, helped draft manuscript, and analyzed results. RH helped analyze structure and helped prepare figures. KK designed research, analyzed results, helped draft manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by funding from the University of Otago, the Robert A. Welch Foundation, the National Institutes of Health, the Thrash Foundation and the Foundation for the Centers for Molecular Research in Infectious Diseases. We would like to dedicate this manuscript to John Francis Thrash, MD, a noted philanthropist, physician and businessman from Houston, Texas who generously aided in the establishment of our structural biology laboratory in New Zealand.

References

- Dixon TC, Meselson M, Guillemin J, Hanna PC: **Anthrax**. *N Engl J Med* 1999, **341**(11):815-826.
- Dahlgren CM, Buchanan LM, Decker HM, Freed SW, Phillips CR, Brachman PS: **Bacillus anthracis aerosols in goat hair processing mills**. *Am J Hyg* 1960, **72**:24-31.
- Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O: **The Sverdlovsk anthrax outbreak of 1979**. *Science* 1994, **266**(5188):1202-1208.
- CDC: **Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP)**. *MMWR* 2000, **49**(RR15):1-20.
- Radosavljevic V, Jakovljevic B: **Bioterrorism – types of epidemics, new epidemiological paradigm and levels of prevention**. *Public Health* 2007, **121**(7):549-557.
- Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, et al.: **Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States**. *Emerg Infect Dis* 2001, **7**(6):933-944.
- Read TD, Salzberg SL, Pop M, Shumway M, Umayam L, Jiang L, Holtzapple E, Busch JD, Smith KL, Schupp JM, et al.: **Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis**. *Science* 2002, **296**(5575):2028-2033.
- Lambert MP, Neuhaus FC: **Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W**. *J Bacteriol* 1972, **110**(3):978-987.
- Silverman RB: **The potential use of mechanism-based enzyme inactivators in medicine**. *J Enzyme Inhib* 1988, **2**(2):73-90.
- Todd SJ, Moir AJ, Johnson MJ, Moir A: **Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium**. *J Bacteriol* 2003, **185**(11):3373-3378.
- Titball RW, Manchee RJ: **Factors affecting the germination of spores of Bacillus anthracis**. *J Appl Bacteriol* 1987, **62**(3):269-273.
- McKevitt MT, Bryant KM, Shakir SM, Larabee JL, Blanke SR, Lovchik J, Lyons CR, Ballard JD: **Effects of endogenous D-alanine synthase and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections**. *Infect Immun* 2007, **75**(12):5726-5734.
- Delvecchio VG, Connolly JP, Alefantis TG, Walz A, Quan MA, Patra G, Ashton JM, Whittington JT, Chafin RD, Liang X, et al.: **Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis**. *Appl Environ Microbiol* 2006, **72**(9):6355-6363.
- Huang CM, Foster KW, DeSilva TS, Van Kampen KR, Elmets CA, Tang DC: **Identification of Bacillus anthracis proteins associated with germination and early outgrowth by proteomic profiling of anthrax spores**. *Proteomics* 2004, **4**(9):2653-2661.
- Veerapandian B: **Three Dimensional Structure-Aided Drug Design**. In *Burger's Medicinal Chemistry and Drug Discovery Volume 1*. 5th edition. Edited by: Wolff ME. New York, New York: John Wiley & Sons, Inc.; 1995:303-348.
- Marrone TJ, Briggs JM, McCammon JA: **Structure-based drug design: computational advances**. *Annu Rev Pharmacol Toxicol* 1997, **37**:71-90.
- Blundell TL: **Structure-based drug design**. *Nature* 1996, **384**(Supp):23-26.
- Blythe MJ, Flower DR: **Benchmarking B cell epitope prediction: underperformance of existing methods**. *Protein Sci* 2005, **14**(1):246-248.
- Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F, Blackman MJ, Faber BW, Remarque EJ, Kocken CH, et al.: **Crystal structure of the malaria vaccine candidate apical membrane antigen 1**. *Science* 2005, **308**(5720):408-411.
- Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L: **Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum**. *Cell* 2005, **122**(2):183-193.
- Morollo AA, Petsko GA, Ringe D: **Structure of a Michaelis complex analogue: propionate binds in the substrate carboxylate site of alanine racemase**. *Biochemistry* 1999, **38**(11):3293-3301.
- Shaw JP, Petsko GA, Ringe D: **Determination of the structure of alanine racemase from Bacillus stearothermophilus at 1.9 Å resolution**. *Biochemistry* 1997, **36**(6):1329-1342.
- LeMagueres P, Im H, Dvorak A, Strych U, Benedik M, Krause KL: **Crystal structure at 1.45 Å resolution of alanine racemase**

- from a pathogenic bacterium, *Pseudomonas aeruginosa*, contains both internal and external aldimine forms. *Biochemistry* 2003, **42(50)**:14752-14761.
24. Fenn TD, Stamper GF, Morollo AA, Ringe D: **A side reaction of alanine racemase: transamination of cycloserine.** *Biochemistry* 2003, **42(19)**:5775-5783.
 25. Stamper GF, Morollo AA, Ringe D: **Reaction of alanine racemase with L-aminoethylphosphonic acid forms a stable external aldimine.** *Biochemistry* 1998, **37(29)**:10438-10445.
 26. LeMagueres P, Im H, Ebalunode J, Strych U, Benedik MJ, Briggs JM, Kohn H, Krause KL: **The 1.9 Å crystal structure of alanine racemase from *Mycobacterium tuberculosis* contains a conserved entryway into the active site.** *Biochemistry* 2005, **44(5)**:1471-1481.
 27. Noda M, Matoba Y, Kumagai T, Sugiyama M: **Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product.** *J Biol Chem* 2004, **279(44)**:46153-46161.
 28. Au K, Ren J, Walter TS, Harlos K, Nettleship JE, Owens RJ, Stuart DI, Esnouf RM: **Structures of an alanine racemase from *Bacillus anthracis* (BA0252) in the presence and absence of (R)-L-aminoethylphosphonic acid (L-Ala-P).** *Acta Crystallogr Sect F Struct Biol Cryst Commun* 2008, **64(Pt 5)**:327-333.
 29. Kobayashi M, Kubota M, Matsuura Y: **Crystallization and improvement of crystal quality for x-ray diffraction of maltotigosyl trehalose synthase by reductive methylation of lysine residues.** *Acta Crystallogr D Biol Crystallogr* 1999, **55(Pt 4)**:931-933.
 30. Kurinov IV, Mao C, Irvin JD, Uckun FM: **X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues.** *Biochem Biophys Res Commun* 2000, **275(2)**:549-552.
 31. Rayment I, Rypniewski WR, Schmidt-Base K, Smith R, Tomchick DR, Benning MM, Winkelmann DA, Wesenberg G, Holden HM: **Three-dimensional structure of myosin subfragment-1: a molecular motor.** *Science* 1993, **261(5117)**:50-58.
 32. Saxena AK, Singh K, Su HP, Klein MM, Stowers AW, Saul AJ, Long CA, Garboczi DN: **The essential mosquito-stage P25 and P28 proteins from *Plasmodium ferox* form tile-like triangular prisms.** *Nat Struct Mol Biol* 2006, **13(1)**:90-91.
 33. Schubot FD, Waugh DS: **A pivotal role for reductive methylation in the de novo crystallization of a ternary complex composed of *Yersinia pestis* virulence factors YopN, SycN and YscB.** *Acta Crystallogr D Biol Crystallogr* 2004, **60(Pt 11)**:1981-1986.
 34. Walter TS, Meier C, Assenberg R, Au KF, Ren J, Verma A, Nettleship JE, Owens RJ, Stuart DI, Grimes JM: **Lysine methylation as a routine rescue strategy for protein crystallization.** *Structure* 2006, **14(11)**:1617-1622.
 35. Kim Y, Quartey P, Li H, Volkart L, Hatzos C, Chang C, Nocek B, Cuff M, Osipiuk J, Tan K, et al.: **Large-scale evaluation of protein reductive methylation for improving protein crystallization.** *Nat Methods* 2008, **5(10)**:853-854.
 36. Read TD, Peterson SN, Tourasse N, Baillie LW, Paulsen IT, Nelson KE, Tettelin H, Fouts DE, Eisen JA, Gill SR, et al.: **The genome sequence of *Bacillus anthracis* Ames and comparison to closely related bacteria.** *Nature* 2003, **423(6935)**:81-86.
 37. Huang CM, Elmets CA, Tang DC, Li F, Yusuf N: **Proteomics reveals that proteins expressed during the early stage of *Bacillus anthracis* infection are potential targets for the development of vaccines and drugs.** *Genomics Proteomics Bioinformatics* 2004, **2(3)**:143-151.
 38. Strych U, Penland RL, Jimenez M, Krause KL, Benedik MJ: **Characterization of the alanine racemases from two mycobacteria.** *FEMS Microbiol Lett* 2001, **196(2)**:93-98.
 39. Inagaki K, Tanizawa K, Badet B, Walsh CT, Tanaka H, Soda K: **Thermostable alanine racemase from *Bacillus stearothermophilus*: molecular cloning of the gene, enzyme purification, and characterization.** *Biochemistry* 1986, **25(11)**:3268-3274.
 40. Strych U, Huang HC, Krause KL, Benedik MJ: **Characterization of the alanine racemases from *Pseudomonas aeruginosa* PAO1.** *Curr Microbiol* 2000, **41(4)**:290-294.
 41. Strych U, Benedik MJ: **Mutant analysis shows that alanine racemases from *Pseudomonas aeruginosa* and *Escherichia coli* are dimeric.** *J Bacteriol* 2002, **184(15)**:4321-4325.
 42. Boggetto N, Reboud-Ravaux M: **Dimeric Inhibitors of HIV-1 Protease.** *Biol Chem* 2002, **383(9)**:1321-1324.
 43. Song M, Rajesh S, Hayashi Y, Kiso Y: **Design and Synthesis of New Inhibitors of HIV-1 Protease Dimerization with Conformationally Constrained Templates.** *Bioorg Med Chem Lett* 2001, **11(18)**:2465-2468.
 44. Strosberg AD: **Breaking the spell: drug discovery based on modulating protein-protein interactions.** *Expert Rev Proteomics* 2004, **1(2)**:141-143.
 45. Wu D, Hu T, Zhang L, Chen J, Du J, Ding J, Jiang H, Shen X: **Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from *E. coli*: Enzymatic characterization with crystal structure analysis.** *Protein Sci* 2008, **17(6)**:1066-1076.
 46. Au K, Berrow NS, Blagova E, Boucher IW, Boyle MP, Brannigan JA, Carter LG, Dierks T, Folkers G, Grenha R, et al.: **Application of high-throughput technologies to a structural proteomics-type analysis of *Bacillus anthracis*.** *Acta Crystallogr D Biol Crystallogr* 2006, **62(Pt 10)**:1267-1275.
 47. Rauer W, Eddine AN, Kaufmann SH, Weiss MS, Janowski R: **Reductive methylation to improve crystallization of the putative oxidoreductase Rv0765c from *Mycobacterium tuberculosis*.** *Acta Crystallogr Sect F Struct Biol Cryst Commun* 2007, **63(Pt 6)**:507-511.
 48. Rypniewski WR, Holden HM, Rayment I: **Structural consequences of reductive methylation of lysine residues in hen egg white lysozyme: an X-ray analysis at 1.8-Å resolution.** *Biochemistry* 1993, **32(37)**:9851-9858.
 49. Strych U, Davlieva M, Longtin JP, Murphy EL, Im H, Benedik MJ, Krause KL: **Purification and preliminary crystallization of alanine racemase from *Streptococcus pneumoniae*.** *BMC Microbiol* 2007, **7**:40.
 50. Jancarik J, Kim S-H: **Sparse matrix sampling: a screening method for crystallization of proteins.** *J Appl Crystallogr* 1991, **24**:409-411.
 51. Leslie AGW: **Recent changes to the MOSFLM package for processing film and image plate data.** *Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography* 1992, **26**:27-33.
 52. Evans PR: **SCALA, version 3.1.9.** Medical Research Council Laboratory of Molecular Biology, Cambridge, UK 1993.
 53. CCP4 suite: **The CCP4 suite: programs for protein crystallography.** *Acta Crystallogr D Biol Crystallogr* 1994, **50(Pt 5)**:760-763.
 54. Vagin A, Teplyakov A: **MOLREP: an automated program for molecular replacement.** *J Appl Cryst* 1997, **30**:1022-1025.
 55. Matthews BW: **Solvent Content of Protein Crystals.** *J Mol Biol* 1968, **33**:491-497.
 56. Emsley P, Cowtan K: **Coot: model-building tools for molecular graphics.** *Acta Crystallogr D Biol Crystallogr* 2004, **60(Pt 12 Pt 1)**:2126-2132.
 57. Murshudov GN, Vagin AA, Dodson EJ: **Refinement of macromolecular structures by the maximum-likelihood method.** *Acta Crystallogr D Biol Crystallogr* 1997, **53(Pt 3)**:240-255.
 58. Schomaker V, Trueblood KN: **On the rigid-body motion of molecules in crystals.** *Acta Cryst, Section B* 1968, **24(1)**:63-76.
 59. Krissinel E, Henrick K: **Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions.** *Acta Crystallogr D Biol Crystallogr* 2004, **60(Pt 12 Pt 1)**:2256-2268.
 60. Krissinel E, Henrick K: **Inference of macromolecular assemblies from crystalline state.** *J Mol Biol* 2007, **372(3)**:774-797.
 61. Vriend G: **WHAT IF: a molecular modeling and drug design program.** *J Mol Graph* 1990, **8(1)**:52-56.
 62. Rodriguez R, Chinea G, Lopez N, Pons T, Vriend G: **Homology modeling, model and software evaluation: three related resources.** *CABIOS* 1998, **14**:523-528.
 63. O'Sullivan O, Suhre K, Abergel C, Higgins DG, Notredame C: **3DCoffee: combining protein sequences and structures within multiple sequence alignments.** *J Mol Biol* 2004, **340(2)**:385-395.